| Title | Non-targeted lipid metabolomics analysis |
|---|---|
| Description | Non-targeted lipidomics is a systematic approach to studying lipid substances within organisms, analyzing the entire lipid system to comprehensively understand lipid molecules and their changes in biological samples. We employ LC-MS/MS mass spectrometry to detect and identify diverse known and unknown lipid molecules, uncovering lipid metabolic pathways, biomarkers, and their mechanisms associated with biological processes. This approach is now extensively applied in cardiovascular disease, cancer, and metabolic disorder research, aiding in the discovery of potential therapeutic targets and biomarkers. |
| Organism | Mus musculus |
| Data Type | Lipidome Data by Mass Spectrometry (MS) |
| Data Accessibility | Open-access |
| BioProject | PRJCA053926 |
| Release Date | 2025-12-19 |
| Submitter | qi li (251133842@qq.com) |
| Organization | Chengdu University, Chengdu, Sichuan Province, China |
| Submission Date | 2025-12-18 |
HTTP download speed may be slow. It is highly recommended that you download the dataset using a dedicated FTP tool (such as FileZilla Client).
| File ID | File Title | Number/Samples | File Type | File Size | File Suffix | Download |
|---|---|---|---|---|---|---|
| OMIX013807-01 | all_combined_metabolites | 1535 | Lipidome Data by Mass Spectrometry (MS) | 2.05 MB | xlsx | |
| OMIX013807-02 | all_negative_metabolites | 627 | Lipidome Data by Mass Spectrometry (MS) | 851.44 KB | xlsx | |
| OMIX013807-03 | POS | 35 | Lipidome Data by Mass Spectrometry (MS) | 3.69 GB | zip | |
| OMIX013807-04 | all_positive_metabolites | 1129 | Lipidome Data by Mass Spectrometry (MS) | 1.51 MB | xlsx | |
| OMIX013807-05 | NEG | 35 | Lipidome Data by Mass Spectrometry (MS) | 2.08 GB | zip | |
| OMIX013807-06 | Compounds-lipids | 2391 | Lipidome Data by Mass Spectrometry (MS) | 8.12 MB | xlsx |
| Paper Title | Journal Name | Publish Time | Accession | Citing Type |
|---|---|---|---|---|
| Schisandra chinensis alleviates Hypertriglyceridemia in nonalcoholic fatty liver disease by modulating the gut microbiota and hepatic lipid metabolism: identification of its active fractions | Frontiers in Pharmacology | 2026-01 | OMIX013807 | Deposit |